Global View Capital Management LLC Sells 26 Shares of Eli Lilly and Company (NYSE:LLY)

Global View Capital Management LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 517 shares of the company’s stock after selling 26 shares during the quarter. Global View Capital Management LLC’s holdings in Eli Lilly and Company were worth $427,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Redwood Investments LLC grew its stake in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company’s stock worth $1,705,000 after acquiring an additional 12 shares during the period. Hobbs Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after acquiring an additional 12 shares during the period. Hixon Zuercher LLC grew its stake in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after acquiring an additional 12 shares during the period. O Brien Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after acquiring an additional 12 shares during the period. Finally, Ascent Capital Management LLC grew its stake in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after acquiring an additional 12 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Guggenheim dropped their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Leerink Partners reissued a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $964.88.

Eli Lilly and Company Price Performance

LLY stock opened at $701.51 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53. The company’s fifty day moving average price is $764.55 and its 200-day moving average price is $794.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $663.95 billion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the firm earned $3.92 earnings per share. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.